Last updated: February 27, 2026
What is NDC 57664-0663?
NDC 57664-0663 refers to a specific drug product listed in the United States National Drug Code directory. The code corresponds to Xyrem (sodium oxybate), a medication approved by the FDA for treating narcolepsy with cataplexy. It is a high-cost, specialized medication primarily used in sleep disorder management.
Market Size and Demand Dynamics
Treatment Population
- Estimated annual market size in the U.S.: 150,000 to 200,000 patients affected by narcolepsy, with approximately 25% requiring sodium oxybate therapy.
Key Drivers
- Increasing diagnosis rates: Rising awareness and better diagnosis protocols have increased treatment rates.
- Restricted prescribing: Due to abuse potential, strict distribution channels and REMS programs limit prescriptions.
- Orphan drug status: Xyrem qualifies as an orphan drug, impacting market exclusivity until at least 2027.
Competitive Landscape
- Primary competitor: Xywav (calcium, magnesium, potassium, and sodium oxybates) by Jazz Pharmaceuticals.
- Other therapies: Modafinil, sodium oxybate off-label uses, off-label sleep aid applications.
- Market share: Xyrem dominates with over 90% of the sodium oxybate segment due to FDA approval and established clinician preference.
Regulatory Status
- FDA approval granted in 2002 for narcolepsy with cataplexy.
- REMS program maintains tight controls on distribution.
- Patent landscape: The original patent expired in early 2000s; however, orphan drug status maintains market exclusivity.
Price Trends and Projections
Historical Pricing
| Year |
Average Wholesale Price (AWP) |
Retail Price |
Notes |
| 2020 |
$47,000 per 750 mL bottle |
$60,000 |
Price stabilized post patent expiration |
| 2021 |
Slight increase (~2%) |
+$1,000 |
Due to inflation and supply chain adjustments |
| 2022 |
Maintained |
$60,000 |
No significant price changes |
Current Pricing
- Average retail price: approximately $60,000 per 750 mL bottle.
- Per patient annual cost: estimates range from $35,000 to $55,000, depending on dosing.
Future Price Projections
- Short-term (next 2 years): Price stability expected due to regulatory restrictions and limited competition.
- Medium-term (3–5 years): Potential for price increase of 3–5% annually due to inflating healthcare costs, supply chain factors, and approval of biosimilars or generics.
- Market security: Remains high due to market exclusivity protections and complex distribution protocols.
Impact of Competition and Biosimilars
- Entry of Xywav has slightly pressured Xyrem prices but has not caused significant reductions due to patent and orphan exclusivity.
- No biosimilar currently approved; biosimilar market development for sodium oxybate is uncertain, likely years away.
Pricing Sensitivity Factors
- Insurance and reimbursement: High variability; payers may negotiate discounts.
- Regulatory changes: Tight controls and REMS impact distribution, stabilizing pricing.
- New therapies: Potential development of alternative sleep disorder treatments could impact market share and pricing.
Market Outlook Summary
| Aspect |
Outlook |
| Market size |
Stable, marginal growth |
| Pricing trend |
Flat to +5% annually |
| Competition |
Limited; dominated by Xyrem |
| Regulatory environment |
Restrictive, stabilizes prices |
Key Takeaways
- The U.S. sodium oxybate market centered around Xyrem remains highly concentrated, with pricing stable due to regulatory and patent protections.
- Price projections forecast minor annual increases driven by healthcare inflation.
- Competition from Xywav offers some market share erosion but has not significantly altered Xyrem’s revenue streams.
- The market's strength depends on ongoing regulatory controls and the absence of biosimilars or generics in the near term.
FAQs
Q1: How does the regulatory environment influence Xyrem's pricing?
A1: Strict REMS restrictions and market exclusivity prevent generic entry, maintaining high prices.
Q2: What factors could lower the drug’s price in the future?
A2: Introduction of biosimilars or generics, major regulatory changes, or market exit due to safety concerns.
Q3: Is the demand for sodium oxybate expected to increase?
A3: Yes, driven by increased diagnosis of narcolepsy and revised treatment guidelines.
Q4: How does Xywav impact Xyrem’s market?
A4: It competes directly on indications and pricing but has not significantly displaced Xyrem.
Q5: What is the outlook for investment in this drug class?
A5: Stable revenue projections with limited downside risks, contingent on ongoing regulatory protections and market conditions.
References
- FDA. (2022). Xyrem (sodium oxybate) Approval and Safety Data. U.S. Food and Drug Administration.
- IMS Health. (2021). US Prescription Market Data for CNS Drugs.
- Jazz Pharmaceuticals. (2022). Xywav Product Information.
- MarketWatch. (2022). Healthcare Drug Pricing Trends 2020-2022.
